Stuttgart - Delayed Quote EUR

AbCellera Biologics Inc (8QQ.SG)

1.7825

-0.0340

(-1.87%)

As of 8:06:26 AM GMT+2. Market Open.

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia, May 14, 2025--AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

Business Wire 10 hours ago

ABCL
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

VANCOUVER, British Columbia, May 12, 2025--AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

Business Wire 2 days ago

ABCL
AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint

AbCellera Biologics ( NASDAQ:ABCL ) First Quarter 2025 Results Key Financial Results Revenue: US$4.24m (down 57% from...

Simply Wall St. 4 days ago

ABCL
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

VANCOUVER, British Columbia, May 09, 2025--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025

Business Wire 5 days ago

ABCL
Q1 2025 Abcellera Biologics Inc Earnings Call

Q1 2025 Abcellera Biologics Inc Earnings Call

Thomson Reuters StreetEvents 5 days ago

ABCL
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite a revenue dip, AbCellera Biologics Inc (ABCL) focuses on advancing clinical programs and strengthening its liquidity position.

GuruFocus.com 5 days ago

ABCL
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 11.76% and 49.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 days ago

ABCL
AbCellera Reports Q1 2025 Business Results

VANCOUVER, British Columbia, May 08, 2025--AbCellera Reports Q1 2025 Business Results

Business Wire 6 days ago

ABCL
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia, April 29, 2025--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.

Business Wire 15 days ago

ABCL
3 Promising Penny Stocks With Market Caps Up To $800M

The U.S. stock market has recently experienced a surge, driven by optimism surrounding reduced tariffs on China and a rally in the technology sector. For investors seeking opportunities beyond established giants, penny stocks—typically smaller or newer companies—present intriguing possibilities for growth and diversification. While the term "penny stocks" may seem outdated, these investments continue to offer potential when supported by strong financials and fundamentals. In this article, we...

Simply Wall St. 21 days ago

CLNE

ABCL

BRSP
Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?

We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where AbCellera Biologics Inc. (NASDAQ:ABCL) stands against other best Canadian penny stocks to invest in now. We define penny stocks as shares trading under $5.00, which usually fall into […]

Insider Monkey 21 days ago

ABCL
AbCellera to Participate at Upcoming Investor Conferences in May and June

VANCOUVER, British Columbia, April 08, 2025--AbCellera to Participate at Upcoming Investor Conferences in May and June

Business Wire last month

ABCL
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

VANCOUVER, British Columbia, April 03, 2025--AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Business Wire last month

ABCL
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia, March 25, 2025--AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Business Wire last month

ABCL
Rapid Micro Biosystems And 2 Other Promising Penny Stocks To Consider

As the U.S. stock market shows signs of recovery with the S&P 500 and Nasdaq slightly higher, investors are closely monitoring economic indicators and policy developments. Amid these conditions, penny stocks—though a somewhat outdated term—remain an intriguing investment area for those seeking potential growth opportunities in smaller or newer companies. When supported by strong financial health, these stocks can offer unique value propositions, making them noteworthy considerations for...

Simply Wall St. last month

TTI

RPID

ABCL
AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

AbCellera Biologics ( NASDAQ:ABCL ) Full Year 2024 Results Key Financial Results Revenue: US$28.8m (down 24% from FY...

Simply Wall St. 2 months ago

ABCL
Q4 2024 Abcellera Biologics Inc Earnings Call

Q4 2024 Abcellera Biologics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

ABCL
AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ...

Despite a net loss increase and revenue decline, AbCellera Biologics Inc (ABCL) focuses on advancing clinical programs and strengthening its financial position.

GuruFocus.com 2 months ago

ABCL
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2024.

Motley Fool 2 months ago

ABCL

ABBV
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 26.67% and 40.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ABCL

Performance Overview

Return	8QQ.SG	S&P 500 (^GSPC)
YTD	-35.74%	+0.19%
1-Year	-47.74%	+11.01%
3-Year	-74.68%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbCellera Biologics Inc (8QQ.SG)

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

Q1 2025 Abcellera Biologics Inc Earnings Call

AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

3 Promising Penny Stocks With Market Caps Up To $800M

Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Rapid Micro Biosystems And 2 Other Promising Penny Stocks To Consider

AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Q4 2024 Abcellera Biologics Inc Earnings Call

AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ...

AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

Performance Overview